Company news

GSK plc news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Positive data for low carbon version Ventolin MDI

October 22, 2025

Latozinemab data read out

October 22, 2025

Positive CHMP Opinion for GSK on Shingrix PFS

October 21, 2025

GSK share positive Ph3 data on tebipenem HBr

October 21, 2025

SCYNEXIS and GSK Resolve Their Disagreement Related to the Restart of the Phase 3 MARIO Study

October 15, 2025

GSK receives expanded Shingrix approval in China

October 14, 2025

New Local Data in GSK and IQVIA's Vaccine Track Supports Smarter Public Health Action at the Community Level

October 1, 2025

GSK - third tranche of share buyback programme

September 30, 2025

GSK appoints CEO designate

September 29, 2025

GSK US Investment Announcement

September 17, 2025

BioGene Therapeutics Inc. Appoints Dr. Francis Tavares, PhD., as Chief Technology Officer

August 20, 2025

FDA to review gonorrhea indication for gepotidacin

August 11, 2025

CureVac/BioNTech mRNA patent litigation settlement

August 8, 2025

Influenza Vaccine Market Research Report 2025-2030 Featuring GSK, Abbott, Pfizer, AstraZeneca, Sanofi, Moderna, CSL, Emergent BioSolutions, BIKEN, Serum Institute of India, Sinovac, GC Biopharma

August 7, 2025

2nd Quarter Results

July 30, 2025

GSK enters Hengrui Pharma collaboration agreements

July 28, 2025

Hengrui Pharma and GSK enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology

July 27, 2025

Blenrep approved in the EU for multiple myeloma

July 24, 2025

US FDA review extended for Blenrep

July 23, 2025

Blenrep US ODAC outcome

July 18, 2025

US FDA Approves GSK’s SHINGRIX in a Prefilled Syringe Presentation

July 17, 2025

GSK’s Shingrix Fully Liquid FDA approval

July 17, 2025

GSK submits Arexvy for adults 18-49 AIR to FDA

July 14, 2025

GSK begins shipping influenza vaccine doses for the 2025-26 flu season

July 10, 2025

Hansa Biopharma appoints Dr Richard Philipson as Chief Medical Officer

July 8, 2025

GSK completes acquisition of efimosfermin for SLD

July 7, 2025

Director Declaration

June 24, 2025

FDA approves Benlysta (belimumab) Autoinjector for children with active lupus nephritis

June 24, 2025

Replacement - Director/PDMR Shareholding

June 23, 2025

Replacement RNS: Linerixibat file accepted by EMA

June 23, 2025

GSK Submits Arexvy for adults 18+ with EMA

June 23, 2025

Arexvy filed in Japan for 18-49 at increased risk

June 20, 2025

GSK announces the Linked by Lupus: Optimal Care Initiative to help support individuals with lupus in the US

June 16, 2025

GSK submits Arexvy for adults 18+ with EMA

June 13, 2025

GSK - second tranche of share buyback programme

June 4, 2025

Linerixibat file accepted for review by US FDA

June 2, 2025

GSK stops Phase 3 trial on cUTIs for efficacy

May 28, 2025

positive CHMP opinion on Blenrep in EU

May 23, 2025

FDA approves Nucala COPD indication

May 23, 2025

Nucala (mepolizumab) approved by US FDA for use in adults with chronic obstructive pulmonary disease (COPD)

May 22, 2025

Blenrep for 2L+ multiple myeloma approved in Japan

May 19, 2025

GSK to acquire efimosfermin

May 14, 2025

Update on belrestotug development programme

May 13, 2025

GSK and Lifetime® launch original movie to raise awareness about the impact of meningitis

May 9, 2025

Linerixibat GLISTEN pIII trial data at EASL

May 8, 2025

Result of AGM

May 7, 2025

Nucala MATINEE data in COPD published in NEJM

May 1, 2025

1st Quarter Results

April 30, 2025

Blenrep licensed by UK MHRA

April 17, 2025

Arexvy now ACIP recommended for 50-59 at risk

April 17, 2025

← Newer news releases · Older news releases →

Calls

The 5 newest of 27 calls. Every call is listed under its year.

Decks

The 5 newest of 181 decks. Every deck is listed under its year.